KR20230027043A - 핵산의 표적화 통합 - Google Patents

핵산의 표적화 통합 Download PDF

Info

Publication number
KR20230027043A
KR20230027043A KR1020227044219A KR20227044219A KR20230027043A KR 20230027043 A KR20230027043 A KR 20230027043A KR 1020227044219 A KR1020227044219 A KR 1020227044219A KR 20227044219 A KR20227044219 A KR 20227044219A KR 20230027043 A KR20230027043 A KR 20230027043A
Authority
KR
South Korea
Prior art keywords
host cell
targeted
soi
sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044219A
Other languages
English (en)
Korean (ko)
Inventor
에이미 션
샤흐람 미사기
신시아 영 람
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20230027043A publication Critical patent/KR20230027043A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/001Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00Vectors comprising a special translation-regulating system
    • C12N2840/002Vectors comprising a special translation-regulating system controllable or inducible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020227044219A 2020-06-24 2021-06-23 핵산의 표적화 통합 Pending KR20230027043A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043409P 2020-06-24 2020-06-24
US63/043,409 2020-06-24
PCT/US2021/038599 WO2021262798A1 (en) 2020-06-24 2021-06-23 Targeted integration of nucleic acids

Publications (1)

Publication Number Publication Date
KR20230027043A true KR20230027043A (ko) 2023-02-27

Family

ID=77168386

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044219A Pending KR20230027043A (ko) 2020-06-24 2021-06-23 핵산의 표적화 통합

Country Status (10)

Country Link
US (2) US20210403943A1 (https=)
EP (1) EP4172346A1 (https=)
JP (1) JP2023532665A (https=)
KR (1) KR20230027043A (https=)
CN (1) CN116096907A (https=)
CA (1) CA3172453A1 (https=)
IL (1) IL299120A (https=)
MX (1) MX2022015205A (https=)
TW (1) TW202216991A (https=)
WO (1) WO2021262798A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI840799B (zh) * 2022-05-02 2024-05-01 國立臺灣海洋大學 水產生物及水產品之外源性分子追溯方法及其系統
KR20250107893A (ko) * 2022-11-15 2025-07-14 제넨테크, 인크. 숙주 세포로의 트랜스포존 매개 통합 및 핵산의 표적 통합의 조합
WO2024229085A2 (en) * 2023-05-01 2024-11-07 Washington State University Mouse model with humanized telomere

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE913929A1 (en) 1990-11-13 1992-05-20 Immunex Corp Bifunctional selectable fusion genes
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
NO2748201T3 (https=) 2011-08-23 2018-05-12
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
CN103152739A (zh) 2013-02-06 2013-06-12 北京奇虎科技有限公司 一种移动终端通话请求信息处理的方法、装置及系统
BR112015031639A2 (pt) * 2013-06-19 2019-09-03 Sigma Aldrich Co Llc integração alvo
TW201620932A (zh) 2014-03-27 2016-06-16 建南德克公司 抗-b型流感病毒血球凝集素抗體及其使用方法
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
BR112017008022A2 (pt) * 2014-10-23 2018-02-20 Regeneron Pharmaceuticals, Inc. célula, polinucleotídeo, veículo, e, métodos para modificação de um genoma de células cho e para preparação de uma proteína de interesse.
US20210309988A1 (en) * 2017-02-07 2021-10-07 Sigma-Aldrich Co. Llc Stable targeted integration
IL275462B2 (en) * 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
AU2019403279A1 (en) * 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
AU2020308002A1 (en) * 2019-06-26 2022-01-20 Genentech, Inc. Randomized configuration targeted integration of nucleic acids

Also Published As

Publication number Publication date
WO2021262798A1 (en) 2021-12-30
CA3172453A1 (en) 2021-12-30
IL299120A (en) 2023-02-01
US20210403943A1 (en) 2021-12-30
CN116096907A (zh) 2023-05-09
TW202216991A (zh) 2022-05-01
JP2023532665A (ja) 2023-07-31
US20250382632A1 (en) 2025-12-18
EP4172346A1 (en) 2023-05-03
MX2022015205A (es) 2023-01-05

Similar Documents

Publication Publication Date Title
KR102699853B1 (ko) 핵산의 표적화된 통합
AU2018223041B2 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
KR102719587B1 (ko) 아데노-관련 바이러스 생산을 위한 포유동물 세포
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
JP2025011135A (ja) 核酸の標的化組込み
AU2016376191A1 (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
CN107223159A (zh) 源自特定细胞类型的dna的检测及相关方法
KR20230034198A (ko) 종양 침윤 림프구의 활성화 및 확장 방법
KR20220024184A (ko) 대장암의 검출
CA2936612A1 (en) Atf6 polymorphisms associated with myocardial infarction, method of detection and uses thereof
KR20180093902A (ko) 태아와 임신 여성간에 상이하게 메틸화된 디엔에이 영역을 이용한 태아 염색체 이수성의 검출
WO1995014772A1 (en) Gene signature
KR20220025749A (ko) 대장암의 검출
KR20220054401A (ko) 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
KR102777514B1 (ko) 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
KR20220025806A (ko) 핵산의 무작위 구성 표적화 통합
KR20230027043A (ko) 핵산의 표적화 통합
KR20100128298A (ko) 카텝신 c의 용도
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
JP2002017375A (ja) 全長cDNA合成用プライマー、およびその用途
KR20120106721A (ko) 신경발생 및 이의 조절에 관련된 유전자, 방법, 그리고 조성물
KR20230093146A (ko) 조류 환우 시기 지연용 조성물 및 조류 환우 시기 지연 물질의 스크리닝 방법
KR102477906B1 (ko) 유도만능 줄기세포 분화 특이적 lncRNA, 및 이의 용도
KR102458464B1 (ko) Snp를 검출 또는 증폭할 수 있는 제제를 포함하는 소의 마블링 지수 판별용 조성물 및 이를 포함하는 키트

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20221216

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240613

Comment text: Request for Examination of Application